Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The present study aimed to evaluate the effect of liver metastases on the efficacy from the combination of PD-1/PD-L1 inhibitor with chemotherapy as first-line treatment in lung cancer using the meta-analysis. A total of 8 randomized controlled trials (RCTs) were included. In patients without liver metastases, PD-1/PD-L1 inhibitor plus chemotherapy could decrease the risk of progression by 40% and risk of death by 29% (HR = 0.60; 95%CI,0.55- 0.65 and HR = 0.71;95%CI,0.58-0.90 respectively). In patients with liver metastases, PD-1/PD-L1 inhibitor plus chemotherapy could decrease the risk of progression by 31% and risk of death by 21% (HR = 0.69;95%CI,0.58-0.81; and HR = 0.79; 95%CI,0.62-0.80, respectively). The pooled ratios of PFS-HRs and OS- HRs reported in lung cancer patients with liver metastases versus those without liver metastases were 1.11 (95%CI, 0.92-1.34) and 1.03 (95%CI, 0.80-1.35), respectively, suggesting that lung cancer patients with and without liver metastases could obtain comparable efficacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.critrevonc.2020.102893 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gastroenteropancreatic neuroendocrine tumors: A retrospective study conducted in the Colombian Southwest.
Rev Gastroenterol Mex (Engl Ed)
September 2025
Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia; Departamento de Medicina Interna, Servicio de Gastroenterología, Fundación Valle del Lili, Cali, Colombia. Electronic address:
Introduction And Aim: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms originating in neuroendocrine cells from the gastric mucosa and submucosa, small intestine, large intestine, rectum, and pancreas. Our aim was to describe their histopathologic, endoscopic, and clinical characteristics and the experience with these tumors at a tertiary care hospital center in the Colombian Southwest.
Materials And Methods: A retrospective, analytic, observational, and descriptive study included 93 patients diagnosed with GEP-NETs, within the time frame of 2018 and 2022.
Is there a chance for curative treatment for metastatic pancreatic adenocarcinoma? A systematic review with meta-analysis.
Langenbecks Arch Surg
September 2025
Department of Surgery HBP Unit, Simone Veil Hospital, University of Reims Champagne-Ardenne, Troyes, France.
Introduction: Pancreatic adenocarcinomas (PDAC) have a poor prognosis, with a 5-year relative Survival rate of 11.5%. Only 20% of patients are initially eligible for resection, and 50% of patients presented with metastatic disease, currently only candidates' palliative treatment.
View Article and Find Full Text PDFCT-Based Radiomics Models with External Validation for Prediction of Recurrence and Disease-Specific Mortality After Radical Surgery of Colorectal Liver Metastases.
Ann Surg Oncol
September 2025
HepatoBiliaryPancreatic Surgery, AOU Careggi, Department of Experimental and Clinical Medicine (DMSC), University of Florence, Florence, Italy.
Purpose: To build computed tomography (CT)-based radiomics models, with independent external validation, to predict recurrence and disease-specific mortality in patients with colorectal liver metastases (CRLM) who underwent liver resection.
Methods: 113 patients were included in this retrospective study: the internal training cohort comprised 66 patients, while the external validation cohort comprised 47. All patients underwent a CT study before surgery.
The Specific Genomic Alterations and Molecular Mechanisms of Liver Metastases in Patients with Lung Adenocarcinoma.
Cancer Invest
September 2025
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Given the limited diagnostic technologies and treatment options available for lung adenocarcinoma (LUAD) patients with liver metastases, it is crucial to identify potential genomic signatures associated with liver metastasis, which could significantly contribute to the development of improved diagnostic tools and treatment strategies for LUAD patients with liver metastases. In this study, we identified specific genetic alterations in tumor samples with liver metastases by targeted capture sequencing. The results showed that the significantly higher mutation frequencies of , and in LUAD patients with liver metastases and and mutations found in both tumor tissues and plasma samples from patients with liver metastases.
View Article and Find Full Text PDFEfficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles.
Hepatology
September 2025
Department of Pathology, Department of Molecular Biology, Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA.
Background And Aims: So far, there is no effective mechanism-based therapeutic agent tailored for liver tumors. Immune checkpoint inhibitors (ICIs) have demonstrated limited efficacy in liver cancer, often associated with severe adverse effects. Although poly-inosinic:cytidylic acid (polyIC) has shown an adjuvant effect when combined with anti-PD-L1 antibody (αPD-L1) in treating liver tumors in animal models, its systemic toxicity limits its clinical utility.
View Article and Find Full Text PDF